Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 15/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28514674 | 0.87 | ALDH1A1 (0.56) | KIF11 | |
| SCHEMBL6551716 | 0.85 | KIF11 (0.61) | KIF11KCNH2CYP2C9CYP2C19CYP3A4 | |
| Ammonia Solution, Strong SCHEMBL2922340 | 0.83 | KIF11 (0.59) | KIF11KCNH2CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL7453762 | 0.83 | KIF11 (0.59) | KIF11KCNH2CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL1149158 | 0.83 | KIF11 (0.64) | KIF11SMN1; SMN2CYP11B1CYP11B2KCNH2 | |
| SCHEMBL5058831 | 0.82 | KIF11 (0.66) | KIF11SMN1; SMN2KCNH2 | |
| SCHEMBL28515838 | 0.82 | KIF11 (0.66) | KIF11SMN1; SMN2KCNH2 | |
| SCHEMBL28596187 | 0.82 | PTPN1 (0.42) | KIF11KCNH2CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL301346 | 0.82 | SMN1; SMN2 (0.55) | KIF11SMN1; SMN2KCNH2CYP2C9CYP2C19 | |
| SCHEMBL9172236 | 0.81 | KIF11 (0.57) | KIF11KCNH2CYP2C9CYP2C19CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116082153-A | Acrylic ester derivative 13 Process for the preparation of C | 长沙贝塔医药科技有限公司 | 2023-05-09 | — | — | CN | claimed |
| CN-116082153-A | Acrylic ester derivative 13 Process for the preparation of C | 长沙贝塔医药科技有限公司 | 2023-05-09 | — | — | CN | disclosed |
| US-8759555-B2 | Stereoselective synthesis of vitamin D analogues | LEO PHARMA A/S (DK) | 2014-06-24 | — | — | US | disclosed |
| US-8362287-B2 | Stereoselective synthesis of vitamin D analogues | LEO PHARMA A/S (DK) | 2013-01-29 | — | — | US | disclosed |
| US-20120271058-A1 | STEREOSELECTIVE SYNTHESIS OF VITAMIN D ANALOGUES | SABROE THOMAS PETER (DK) | 2012-10-25 | — | — | US | disclosed |
| US-8017620-B2 | Dutpase inhibitors | MEDIVIR AB (SE) | 2011-09-13 | — | — | US | disclosed |
| US-8017620-B2 | Dutpase inhibitors | MEDIVIR AB (SE) | 2011-09-13 | — | — | US | disclosed |
| US-8017620-B2 | Dutpase inhibitors | MEDIVIR AB (SE) | 2011-09-13 | — | — | US | disclosed |
| US-20110021459-A1 | DUTPASE INHIBITORS | MEDIVIR AB (SE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021459-A1 | DUTPASE INHIBITORS | MEDIVIR AB (SE) | 2011-01-27 | — | — | US | disclosed |
| EP-0749957-B1 | Aromatic hydroxamic acid compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2000-04-26 | — | — | EP | disclosed |
| CN-1251037-A | Triarylmethane compounds for sickle cell disease | HARVARD COLLEGE (US) | 2000-04-19 | — | — | CN | disclosed |
| US-6028103-A | Triaryl methane compounds and analogues thereof useful for the treatment or prevention of sickle cell disease or diseases characterized by abnormal cell proliferation | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2000-02-22 | — | — | US | disclosed |
| EP-0918514-A1 | TRIARYL METHANE COMPOUNDS FOR SICKLE CELL DISEASE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1999-06-02 | — | — | EP | disclosed |
| US-5891916-A | ANTINEUROGEGERATIVE AGENT | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-04-06 | — | — | US | disclosed |
| US-5874436-A | EFFECTIVE IN INHIBITING THE ACTION OF A BACTERIAL HISTIDINE PROTEIN KINASE; USEFUL AGAINST ANTIBIOTIC RESISTANT ORGANISMS | DEMERS JAMES P (US) | 1999-02-23 | — | — | US | disclosed |
| WO-1997048676-A1 | TRIPHENYLALKYL ANTIMICROBIAL AGENTS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1997-12-24 | — | — | WO | disclosed |
| WO-1997034589-A1 | TRIARYL METHANE COMPOUNDS FOR SICKLE CELL DISEASE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1997-09-25 | — | — | WO | disclosed |
| US-5643950-A | INHIBITORS OF A BACTERIAL HISTIDINE PROTEIN KINASE | ORTHO PHARMACEUTICAL CORPORATION (US) | 1997-07-01 | — | — | US | disclosed |
| EP-0749957-A1 | Aromatic hydroxamic acid compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1996-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120271058-A1 | STEREOSELECTIVE SYNTHESIS OF VITAMIN D ANALOGUES | CYP24A1, CYP2R1, VDR | KIF11 3614/4885SMN1; SMN2 4848/4885CYP11B1 77/4885 |
| US-20110021459-A1 | DUTPASE INHIBITORS | DUT, DHODH, NAT10 | KIF11 2686/4885SMN1; SMN2 2521/4885CYP11B1 1061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.